Health News

WASHINGTON (MedPage Today) — The FDA has formally approved the enzyme replacement therapy velaglucerase alfa (VPRIV) — already okayed for pre-approval marketing — for pediatric and adult patients with Gaucher disease.

Read more

Filed under: Pharmacy News
Tags: Drug, Genetic, Pharmacy

Related posts

• Warning From AMP About Direct Access Genetic Testing (0)
  In response to recent announcements about consumer genetic tests being made available in retail drugstores, the Association for Molecular Pathology (AMP) today reiterated its position that these tests should be provided to the public only through the services of appropriate health care professionals that order tests from laboratories that are certified by CLIA for highcomplexity [...]
  
  
• VUMC doctors to begin statin drug screening for rare genetic variation (0)
  Vanderbilt University Medical Center doctors announced today they will begin screening patients who take commonly prescribed statin drugs for a rare genetic variation that can increase risks for side effects from these drugs such as muscle aches, kidney damage and even death. Read more [tags] Pharmacy News [/tags]
  
  
• Viral Genetics: Company update (0)
  Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer [...]
  
  
• Viral Genetics Updates HIV/AIDS And Drug Resistant Cancer Research Programs (0)
  Viral Genetics, Inc. (Pinksheets: VRAL) continues to make the transition to a clinical-stage company. The Company's two lead pharmaceutical programs -- APi1177 for HIV/AIDS, and various Metabolic Disruption (MDT) compounds for drug-resistant cancers -- are being advanced towards clinical development under sponsor- or investigator-initiated Investigational New Drug (IND) pathways... Read more [tags] Pharmacy News [/tags]
  
  
• Viral Genetics cautions investors and the public to rely only on its press releases and disclosures (0)
  Viral Genetics (Pink Sheets: VRAL), a biotechnology company that develops drug compounds for HIV/AIDS, autoimmune diseases, and cancer, is issuing this announcement in response to a series of press releases distributed by collegestock.com on August 25 and August 26, and an article published on Today's Financial News entitled "TFN Reader Grapevine: There's Something About Viral [...]